Telesis Bio Sees Prelim. 2023 Total Consolidated Revenue Of $27.5M, Up From $27.4M YoY; Sees FY24 Total Revenue $7M, Down From $9.5M YoY
Telesis Bio Sees Prelim. 2023 Total Consolidated Revenue Of $27.5M, Up From $27.4M YoY; Sees FY24 Total Revenue $7M, Down From $9.5M YoY
Telesis Bio預計2023年合併總收入爲2750萬美元，高於同比2740萬美元；預計24財年總收入爲700萬美元，低於同比950萬美元
- Total consolidated revenue for the 2023 fiscal year is expected to be $27.5 million, up slightly from $27.4 million achieved in 2022.
- Total revenue for the fourth quarter of 2023 is expected to be $7.0 million, a 26.3% reduction from $9.5 million for the same period in 2022 due primarily to capital spending weakness in end markets and the resulting mix-shift toward lower-priced BioXp 3250 instruments. Total revenue, excluding BioXp instrument sales and discontinued BioFoundry Services operations, were $20.9 million for the full fiscal-year period, an increase of 12.4% compared to $18.6 million for the same categories in the prior year period.
- 2023財年的總合並收入預計爲2750萬美元，略高於2022年的2740萬美元。
- 2023年第四季度的總收入預計爲700萬美元，較2022年同期的950萬美元下降26.3％，這主要是由於終端市場的資本支出疲軟以及由此導致的向價格較低的BioXP 3250工具的混合轉移。不包括BioXP儀器銷售和已終止的BioFoundry Services業務在內的總收入爲2,090萬美元，與去年同期同類產品的1,860萬美元相比增長了12.4％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。